Nucleonics Signs Agreement to Evaluate Novosom Smarticles Delivery Technology

Sep 03, 2004

Premium

Nucleonics announced last month that it has signed a deal to evaluate Novosom’s Smarticles technology as a way to deliver its expressed interfering RNAi drug candidates for hepatitis B and C, expanding the RNAi-based drug developer’s stable of potential delivery techniques to three.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Not Always an Answer

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

CRISPR Acceptance or Not?

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

This Week in Science

In Science this week: research regulation and reporting requirement reform, and more.

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.